The nation of Zimbabwe has rejected a major American health deal valued at $367m (272 million pounds) over five years because of Washington's insistence on confidential information.
The decision was revealed after a official document from December was leaked, which showed Head of State Emmerson Mnangagwa deemed the deal was "unbalanced".
A government representative later clarified that the US was requesting genetic material for research and profit while was unwilling to share the resulting advantages from future vaccines.
"We must now begin the difficult and regrettable task of ending our health aid in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy noted the United States had donated over $1.9bn as health assistance to Zimbabwe over the last twenty years.
A doctors' association in Zimbabwe has urged more negotiations to reach a deal acceptable to all parties so the nation's critical HIV treatment initiative can continue.
Broader Implications
Zimbabwe's decision follows a comparable case in neighbouring Kenya, where a court suspended a related deal with the US after legal challenges were filed about the security of citizens' medical information.
Since returning to office last year, US President Donald Trump has slashed foreign aid and shut down the key foreign aid agency.
USAID had administered assistance for the American government, but Trump argued its spending was "wasteful" and his administration was seeking government-to-government agreements to boost openness and responsibility.
As per reports, Sixteen African countries have to date signed these new health pacts, representing over $18.3bn in committed funds.
Specifics of the Declined Agreement
This assistance for Zimbabwe was intended to funded "tackling HIV/Aids, tuberculosis, malaria, maternal and child health, and disease outbreak preparedness.
"We believe this collaboration might have yielded significant advantages for the people of Zimbabwe, especially the 1.2 million men, women and children presently on HIV treatment via American-funded initiatives," the Ambassador said.
However, official spokesman Nick Mangwana said the proposed deal was "unfair".
"Our nation was requested to surrender its biological resources and data indefinitely, without any corresponding promise of benefiting from any scientific breakthroughs – like vaccines, diagnostics, or treatments – that might be developed from that provided information," his statement read.
"Put simply, our country would provide the raw materials for medical research with no assurance that the final treatments would be accessible to our citizens should a new pandemic emerge."
National Interest and Global Health
He also pointed out that the US's withdrawal from the World Health Organization (WHO) and its push of one-on-one deals were upending structures already set up via the international organization.
The spokesperson gave as an example its Pandemic Benefit-Sharing system designed to deal with potential global health emergencies.
"This framework is designed to guarantee that when a country provides its data, the benefits – including medicines and cures – are shared equitably, not commercialised solely by those with the funds to develop them."
The government's concerns over the US deal "are not meant as anti-American sentiment," Mangwana stressed.
"We encourage continued discussions with our US partners on how subsequent co-operation could be arranged in a manner that respects the independence and interests of both nations."
Health Experts Reaction
Medical experts expressed it recognised the government's concerns, but recommended that talks must proceed since a large portion of the country's HIV programmes were funded by foreign aid.
"Where specific concerns arise, including those involving data governance or agreement terms, these can frequently be resolved through detailed discussion and negotiated safeguards," it said.
This impasse underscores the ongoing challenges between receiving vital foreign assistance and safeguarding a country's data in an increasingly interconnected world.